facebook
twitter
rss
account
search
search
 

Rosy Phase 1 results for ImmunoGen drug

Nov. 16, 2005 at 2:15 PM   |   Comments

CAMBRIDGE, Mass., Nov. 16 (UPI) -- ImmunoGen said Wednesday that its investigational drug dubbed huN901-DM1 shows promise in fighting solid tumors.

The compound appears to cause complete remission in patients with small-cell lung cancer or other CD56-expressing solid tumors, lasting at least 15 weeks, and disease stability lasting up to 18 weeks, the Cambridge, Mass.-based firm said in a statement.

ImmunoGen presented its Phase 1 clinical findings on the tumor-activated prodrug compound at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.

In the ongoing trial, the drug is being administered daily for three consecutive days in a 21-day cycle to patients with CD56-expressing solid tumors, ImmunoGen said.

New cohorts of patients receive progressively higher doses of huN901-DM1 until the maximum tolerated dose is established, the company said.

All study patients have relapsed or refractory small-cell lung cancer (SCLC) or other CD56-expressing solid tumors.

© 2005 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Most Popular
1
Vast majority of oncologists admit to burnout Vast majority of oncologists admit to burnout
2
France considers plain cigarette packaging France considers plain cigarette packaging
3
Ebola virus contained in Nigeria and Senegal Ebola virus contained in Nigeria and Senegal
4
Morning exercise helps calm ADHD symptoms in children Morning exercise helps calm ADHD symptoms in children
5
CDC: Diabetes rates leveling off CDC: Diabetes rates leveling off
Trending News
x
Feedback